AI Insight: Vertex Pharmaceuticals trades slightly above its fair value by 2.9%, with strong financial health and high confidence in multiple valuation methods. Monte Carlo analysis shows extreme volatility and substantial downside risk (64.7%) despite a median valuation below current price. This reflects significant uncertainty and a wide range of potential outcomes for investment return.